Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: A double-blind randomized, controlled trial

Journal of Tropical Pediatrics

Volumn 58, Issue 5, 2012, Pages 375-381

  Gupta, Sumita ^a   Ahmed, Faizan ^b   Lodha, Rakesh ^a   Gupta, Y K ^a   Kabra, Sushil K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Cystic fibrosis; FEV1; Forced vital capacity (FVC); Hypertonic saline

Indexed keywords

SALBUTAMOL; SODIUM CHLORIDE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION; LUNG FUNCTION; MALE; NEBULIZATION; PATIENT COMPLIANCE; PREDICTION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SPIROMETRY; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, INHALATION; ADOLESCENT; CHILD; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; NEBULIZERS AND VAPORIZERS; RESPIRATORY FUNCTION TESTS; SALINE SOLUTION, HYPERTONIC; SPIROMETRY; TREATMENT OUTCOME;

EID: 84867364343     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fms004     Document Type: Article

References (23)

1. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006;173:475-82.
2. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion; not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-15.
3. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004;23: 146-58.
4. Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007; 13:231-40.
5. Tarran R, Donaldsen S, Boucher RC, et al. Rationale for hypertonic saline therapy for cystic fibrosis lung disease. Semin Respir Crit Care Med 2007;28:295-302.
6. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Eng J Med 2006;354:241-50.
7. Riedler J, Reade T, Button B, et al. Inhaled hypertonic saline increase sputum expectoration in cystic fibrosis. J Paediatr Child Health 1996;32:48-50.
8. Elkins MR, Robinson MR, Rose BR, et al. A controlled trial of long term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354: 229-40.
9. Narang I, Pike S, Rosenthal M, et al. Three-minute step test to assess exercise capacity in children with cystic fibrosis with mild lung disease. Pediatr Pulmonol 2003;35:108-13.
10. Taussig LM, Chernick V, Wood R, et al. Standardization of lung function testing in children. J Pediatr 1980;97: 668-76.
11. Prasad SA, Randall SD, Balfour-Lynn IM, et al. Fifteen-count breathlessness score: an objective measure for children. Pediatr Pulmonol 2000;30:56-62.
12. Eng PA, Morton J, Douglass JA, et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77-83.
13. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52:900-3.
14. Robinson M, Regnis JA, Bailey DL, et al. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996;153:1503-9.
15. Ballmann M, Hardt HVD. Hypertonic saline and recombinant human DNase: a randomized cross-over pilot study in patients with cystic fibrosis. J Cyst Fibros 2002;1:35-37.
16. Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomized trial. Lancet 2001;358:1316-21.
17. Adde FV, Borges KTL, Hatanaka ACF, et al. Hypertonic saline X recombinant human DNase a randomized cross-over study in 18 cystic fibrosis patients. J Cyst Fibros 2004;3(Suppl 1):552-66.
18. Weller P, Ingram D, Preece M, et al. Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax 1980;35:42-6.
19. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999;14: 678-85.
20. Smith JJ, Travis SM, Greenberg EP, et al. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-36.
21. Rodwell LT, Anderson SD. Airway responsiveness to hyperosmolar saline challenge in cystic fibrosis: a pilot study. Pediatr Pulmonol 1996;21:282-9.
22. Kastelik JA, Aziz I, Morice AH, et al. Sputum induction in young cystic fibrosis patients. Eur Respir J 2001; 17:1.
23. Aziz I, Kastelik JA, et al. Hypertonic saline for cystic fibrosis. N Eng J Med 2006;354:1848-51.